A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).

4570 Background: Inhibiting VEGF and mTOR pathways are standard treatment approaches for patients (pts) with mRCC. Combinations of these agents have potential to improve efficacy. Here we report th...